Oragenics Inc. Secures $16.5 Million to Advance Intranasal Concussion Therapy
Oragenics Inc. (NYSE American: OGEN), a clinical-stage biotechnology company, has successfully closed a public offering of Series H Convertible Preferred Stock and Warrants, amassing approximately $16.5 million in gross proceeds. This financial achievement underscores the company’s commitment to advancing its intranasal therapeutics for neurological disorders, particularly its ONP-002 treatment for concussions. The offering involved the […]